Skip to main content

Targeting of angiogenic tgf-b signalling in cancer and cardiovascular diseases

Objective

Diseases as common as cancer, diabetes associated blindness and coronary arteriosclerosis, and as rare as hereditary hemorrhagic telangiecstasia (HHT), a chronic, bleeding ailment, would benefit from exogenous control of angiogenesis. Gene ablation in mice has shown that the transforming growth factor (TGF) beta signal transduction pathway is essential for normal vasculogenesis and angiogenesis while mutations in TGF beta-receptors cause HHT. Treatments of vascular disease based on interference with local ligand concentrations are not feasible because of side effects on the immune system and fibrosis. Here, we will use state-of-the-art technology to identify target genes downstream of activated receptors in vascular cells and develop cell culture and animal models for vascular disease associated with defective TGF beta signalling.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

UNIVERSITY OF IOANNINA
Address

45110 Ioannina
Greece

Participants (5)

FLANDERS INTERUNIVERSITY INSTITUTE FOR BIOTECHNOLOGY VZW
Belgium
Address
Herestraat 49, Campus Gasthuisberg, Bedg. "O&h"
3000 Louvain / Leuven
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
Address
Rue Des Martyrs 17
38054 Grenoble
NETHERLANDS INSTITUTE FOR DEVELOPMENTAL BIOLOGY
Netherlands
Address
Uppsalalaan 8
3584 CT Utrecht
THE NETHERLANDS CANCER INSTITUTE / ANTONI VAN LEEUWENHOEK HOSPITAL
Netherlands
Address
121,Plesmanlaan 121
1066 CX Amsterdam
UNIVERSITY OF NEWCASTLE UPON TYNE
United Kingdom
Address
Framlington Place
NE2 4HH Newcastle Upon Tyne